Cencora, Inc. filings document material events for a NYSE-listed pharmaceutical distribution and healthcare solutions company. Recent 8-K disclosures furnish quarterly operating results, Regulation FD information, executive officer transition details, annual meeting voting results and entries into material definitive agreements.
The company’s regulatory record also covers capital-structure matters, including common stock and listed senior notes, registered public debt offerings and the terms of multiple senior note maturities. Governance filings describe director elections and other shareholder voting matters, while material-event reports connect financing activity and completed acquisitions to the company’s operating and financial disclosures.
Cencora, Inc. (symbol: COR) has filed a Form 144 with the U.S. Securities and Exchange Commission, indicating a proposed insider sale of common stock under Rule 144.
The notice covers the potential disposition of 1,000 common shares through broker Goldman Sachs & Co. LLC. The sale is tentatively scheduled for 18 June 2025 on the NYSE. At a stated aggregate market value of $293,200, the implied reference price is roughly $293.20 per share.
The filing shows the shares were originally granted to the seller as restricted stock awards on two dates—20 Aug 2013 (500 shares) and 09 Aug 2016 (500 shares)—as part of compensation from Cencora. No prior sales have been reported in the past three months, and the person filing affirms no knowledge of undisclosed material adverse information about the company.
Relative to the total outstanding share count of 193,823,487, the proposed sale represents approximately 0.0005 % of shares outstanding, suggesting minimal dilution or market impact. The filing is routine in nature, providing transparency around a small insider transaction rather than signaling any broader strategic change.